Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Effectiveness of Thermal Ablation Combined With Anlotinib and TQB2450 Solution for Advanced Hepatocelualr Carcinoma

NCT04665609 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.

NCT NCT04665609
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04665609 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Effectiveness of Thermal Ablation Combined With Anlotinib and TQB2450 Solution for Advanced Hepatocelualr Carcinoma
Lead sponsor
Chinese PLA General Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
March 5, 2021
Completion date
December 31, 2023
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anlotinib, hepatocellular carcinoma, pdl-1, thermal ablation